A Single Center, Randomized, Double-blind , Single-dose, and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of MW032 and Xgeva® in Healthy Adults
Overview
- Phase
- Phase 1
- Intervention
- MW032
- Conditions
- Bone Tumor
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Maximum serum concentration (Cmax)
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW032 and Xgeva® in healthy adults.
Detailed Description
This is a phase I, single center, randomized, double-blind and parallel group clinical trial. The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections of MW032 and Xgeva® in healthy volunteers. The secondary objective are to assess the Clinical safety and immunogenicity similarity of single and subcutaneous injections of MW032 and Xgeva® in healthy volunteers. At the same time, preliminary evaluate the pharmacodynamic similarity between MW032 and Xgeva®. Subjects would receive a single 120mg（1.7mL）of MW032 or Xgeva® through subcutaneous injection.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age: 18-65 years old (including 18 and 65 years old), healthy male subjects.
- •Body mass index (BMI) within the range 19-28kg/m
- •History, physical examination, laboratory tests and test related items of inspection were normal or mildly abnormal clinically insignificant.
- •Volunteered to participate in this clinical trial, capable of giving written informed consentan.
- •The subject (including the subject's partner) takes effective contraceptive measures.
Exclusion Criteria
- •Nervous/mental, respiratory system, cardiovascular system, digestive system, blood and lymphatic system, endocrine system, skeletal and muscular system diseases, liver and kidney dysfunction, or any other diseases and physiological conditions that may affect the results of the study.
- •Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously.
- •Clinical laboratory abnormalities of clinical significance, or other clinical findings suggest clinically significant following diseases (including, but not limited to the gastrointestinal tract, kidney, liver, nerve, blood, endocrine, cancer, lung, immune, mental or cardiovascular disease).
- •Subject has viral hepatitis (including hepatitis B and hepatitis C), AIDS antibodies, and Treponema pallidum antibodies.
- •Those who have used the following drugs within 1 month or 5 half-lives (whichever is longer) before participating in this study, including but not limited to: estrogen-containing contraceptives, bisphosphonates, fluoride, hormone replacement Treatment (ie tibolone, estrogen, estrogen-like compounds, such as raloxifene), calcitonin, strontium, parathyroid hormone or its derivatives, vitamin D supplements (\>1000 IU/day), corticosteroids (inhaled or topical corticosteroids can be used 2 weeks before enrollment), anabolic hormone drugs, calcitriol, diuretics.
Arms & Interventions
MW032
MW032 injection (120mg) by subcutaneous injection once on the first day of treatment.
Intervention: MW032
Xgeva®
Xgeva® injection (120mg) by subcutaneous injection once on the first day of treatment.
Intervention: Xgeva®
Outcomes
Primary Outcomes
Maximum serum concentration (Cmax)
Time Frame: Day0-Day161
Area under the plasma concentration-time curve (AUC0-t )
Time Frame: Day0-Day161
Secondary Outcomes
- serum CTX1(Day0-Day161)
- Adverse events(AE)(Day0-Day161)